| Revenue growth | Consolidated revenue grew 53% YoY to ₹614.12 Cr in H1. |
|---|---|
| Margins | Consolidated margins hit by one-time 2% margin US distribution transaction. |
| Order book | Solid pipeline; recently secured major $12M US order and Bolivia tenders. |
| Demand visibility | Strong international demand across 40+ countries; 1448 products under registration. |
| Management confidence | Highly confident, emphasizing niche products and first-to-market generic status. |
Growth
Consolidated revenue jumped 53% YoY to ₹614 Cr; standalone pharma grew 32% with 30% PAT margins.
Outlook
Targeting 25-30% B2C revenue contribution; H2 expected to outperform H1 based on order book and launches.
Risks
Low-margin US orders ($12M at 2% margin) significantly compress consolidated profitability; building B2C brands involves heavy upfront marketing costs.
Earnings Call Transcript filed with NSE, NSE: REMUS. Summary written with AI assistance from the document.
Remus Pharmaceuticals Ltd: key numbers
- Share price
- ₹815.00
- Market cap
- ₹960.4 Cr
- Revenue (annual)
- ₹853.6 Cr
- Net profit (annual)
- ₹36.99 Cr
- P/E (TTM)
- 26.0×Sector 41.3×
- Promoter holding
- 70.95%
- FII holding
- 5.10%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Remus Pharmaceuticals Ltd
All →Remus Pharmaceuticals Investor Presentation: Key Takeaways
H1-FY27 consolidated revenue INR 6,141 Mn (+53.4%) and PAT INR 247 Mn (+14.4%), with EBITDA margin compressing to 4.87%. Standalone PAT rose 56.7%. Growth comes from tender wins and LATAM/SEA expansion.
Remus Pharmaceuticals Results Update
Remus Pharmaceuticals reported H1 FY27 results with standalone revenue of ₹62.08 Cr (up 32.51%) and consolidated revenue of ₹614.12 Cr (up 53.45%). The media release also highlights new tenders, approvals and portfolio expansion across international markets.
Remus Pharmaceuticals Dividend
Remus Pharmaceuticals has fixed 7 November 2026 as the record date for its 1st interim dividend for FY 2026-27, declared at today's board meeting. The filing does not state the per-share dividend amount.
Remus Pharmaceuticals H1 FY27 Results: Net Profit ₹24.7 Cr, Up 14.4% YoY
Remus Pharmaceuticals Ltd reported revenue from operations of ₹614.1 Cr (+53.4% YoY) and net profit of ₹24.7 Cr (+14.4% YoY) for H1 FY27.
- Key figure
- Net profit ₹24.7 Cr · +14.4% YoY
Remus Pharmaceuticals Other Announcement
Remus Pharmaceuticals filed its Reg 76 Reconciliation of Share Capital Audit Report for Q1 FY2027. It is a routine depository-compliance certificate with no transaction or business event.
Remus Pharmaceuticals Annual General Meeting
Remus Pharmaceuticals Limited shareholders approved the migration of equity shares from the NSE Emerge platform to the main boards of NSE and BSE.